Pharma Journalist

6th Annual Pre-Filled Syringes West Coast Conference
2023-06-12 - 2023-06-13 | San Diego, CA, USA
Assessing Device Development and Regulation for Advanced Innovation
Sponsors: Datwyler, Haselmeier, Mitsubishi Gas Chemical, Nemera, ZEON
Exhibitors: Credence MedSystems, Kymanox, Noble, Owen Mumford Pharmaceutical Services, SCHERDEL Medtec
SAE Media Group’s 7th Annual Pre-Filled Syringes West Coast Conference will be back for 2023 in San Diego to bring together the device developers, innovative biotech, and big pharma.
This year’s conference will explore the exciting advances in the combination product drug delivery space and a future outlook exploring how pharma, device developers and regulators can work together to encourage innovation.
With the injectable drug delivery industry rapidly advancing year-to-year, administration using pre-filled syringes, auto-injectors, and pen-injectors are increasingly common. Innovations in device technology, such as connected devices are leading the way in device design in addition to injectable delivery devices for novel and large volume drugs. With the need for self-administration growing, there is an enhanced demand for on-body injectors and digitalised health as well as patient centricity. We are beginning to see environmental sustainability being incorporated into aspects of device lifecycle from design to manufacturing and the use of the device. This year’s conference looks to address these hot topics through case studies and industry insights.
As part of SAE’s leading injectable drug delivery conferences this is a must attend event; not only will the conference bring delegates key insights to enhance their drug device portfolio, but it will also give them the opportunity to network with key industry players.
Benefits of Attending:

Engage with industry representatives about the latest technologies and advances within the injectable device market and directions to take to advance your device portfolio
Gain insight into new technologies for wearable injectors he delivery of novel and large volume drugs
Understand the latest regulatory requirements and guidance to ensure your combination products are compliant such as meeting essential performance requirements
Delve into aspects of primary packaging such as material components to consider during device design to ensure drug stability and safety
Explore how digital technologies such as companion apps are being incorporated into drug delivery devices to improve user-centricity

Who should attend:
Directors, Heads of Departments and Managers for the following areas:

Device Development
Device Engineering
Combination Product Development
Drug Delivery Devices
Primary Packaging Development
Digital Health
Large Volume Drug Delivery
Novel Drug Product Formulation
Regulatory Affairs

Early Bird Rates:

EB1 – 28 Feb 2023 – US$400
EB2 -31 March 2023 – US$200
EB3 – 28 April 2023 – US$100

Additional Contact Info:
T: +44 (0)20 7827
E: Hannah.Blake@saemediagroup.com
W: http://www.prefilled-syringes-westcoast.com/PharmaJournalist-El

3rd Annual Gene Therapy Patient Engagement
2023-06-13 - 2023-06-15 | Westin Boston Seaport, 425 Summer Street, Boston, MA, 02210, United States
As the global healthcare system accelerates its acceptance of gene therapies as one-time, potentially curative, treatment options for rare diseases, the role of patient engagement in informing drug development strategy is evolving.
At this interface lies the 3rd Gene Therapy Patient Engagement Summit, uniting patient advocacy and engagement experts from leading gene therapy and gene editing drug developers, along with patient groups and patients themselves. Talks, workshops, and group discussions will shed a light on how to better integrate the patient voice into gene therapy programs at crucial stages of the drug development process.
Join us in Boston this summer to gain the actionable insights, tools, and strategies you need to better implement patient input into patient-centric gene therapy programs.
To know more visit: https://ter.li/rbofji

Temperature Control and Logistics Summit
2023-06-13 - 2023-06-15 | Sheraton Frankfurt Airport Hotel & Conference Center, Hugo-Eckener-Ring 15/Terminal 1, Frankfurt am Main, 60549, Germany
Advance your end-to-end logistics strategy to deliver vital therapeutics at the RIGHT TIME, RIGHT PLACE and the RIGHT TEMPERATURE
Join us in Frankfurt in June 2023 in a brand-new venue at the heart of Europe, as once again, we return live and in-person for 3 days of interactive sessions, collaborative roundtables as well as formal and informal networking to maximise the value of shared insights and open discussions.
We meet at a time of great challenge and opportunity. How can we mitigate risk and ensure quality whilst adopting the new technologies essential to future success? In what ways can we bolster the resilience of our supply chains without compromising operational agility? How can we build a supply chain and logistics network that is both effective and environmentally sustainability?
Only in partnering across the supply chain can we confront these challenges; and as a community that thrives on innovation and collaboration, we’ve built a programme centred on the fundamental challenges of our time, including how we:
>> Drive Digital Transformation Throughout The Supply Chain To Achieve Full End-To-End Visibility
>>Enhance Supply Chain & Logistics Network Design To Bolster Resilience, Security & Efficiency
>> Partner Across The Network To Meet The Demands of An Increasingly Complex Operating Environment
>> Leverage New Packaging Innovation To Ensure Quality & Demonstrate Regulatory Compliance
>> Build An Environmentally Sustainability Temperature Controlled Supply Chain
TCL 2023 will provide a deep-dive into what these industry developments mean for Pharmaceutical Logistics, Quality Assurance & Supply Chain practitioners and focus on delivering a mix of interactive sessions, which will enable delegates to leverage the collective knowledge of their peers and brainstorm solutions to the challenges, which the industry is facing.
TCL doesn’t just stand for Temperature Control and Logistics, now it also stands for Transformation, Collaboration and Learning! >> Download the full agenda to view full speaker line-up, discussion details, sponsorship opportunities, and more!

3rd ILD Summit
2023-06-13 - 2023-06-15 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
Returning for the 3rd year, the ILD Summit will lean into the industry’s key challenges, explore pipeline opportunity development, and look towards the future for ILD therapeutic development from idiopathic pulmonary fibrosis pipelines. From illuminating predictors of progression to define and identify the progressive fibrosis phenotypes for patient stratification to evolving clinical trial design with novel secondary and exploratory endpoints beyond FVC. This is a fantastic point in 2023 for the lung fibrosis community to come together to meet at the intersection of pulmonology and rheumatology to advance therapeutic development for ILDs.
To know more visit: https://ter.li/wc2uto

Next Gen Inhalation Delivery Summit
2023-06-20 - 2023-06-22 | The Bostonian, 26 North St, Boston, MA, 02109, United States
With exciting developments in pioneering inhaled drug products from Moderna, Vertex, ReCode Therapeutics, and Pieris Pharmaceuticals, now is the time to go full speed ahead on your efforts into inhaled formulation and delivery optimization. Despite the inhalation drug delivery market being expected to reach $18.6 billion by 2029, achieving cell-specific delivery, and optimized stability remain vital challenges.
This June, the hotly anticipated Next Gen Inhalation Delivery Summit will debut, where we will unite 80+ senior leaders at this definitive meeting dedicated to the inhalation community. Whether your work in COPD, asthma, IPF, lung cancer or infectious disease, this comprehensive forum offers the solution to capitalize on the common goal of targeted lung delivery.
Be part of the conversation in Boston this June, where we unpick:

Overcoming pulmonary biological barriers to minimize dosage and maximize therapeutic benefit
Advancing your inhalation formulation techniques for improved stability and longer shelf-lives
Ensuring device-formulation compatibility with patient compliance and patient convenience

With key speakers from the likes of Janssen, Avalyn Pharma, and FDA, exciting content, and networking opportunities, you cannot afford to miss out!
To know more visit: https://ter.li/hlg9tw

2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit
2023-06-20 - 2023-06-22 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
Exciting results are expected this year, from multiple mid and late stage clinical trials and involving a broad array of adenosine drugs including CD73, CD39 and A2AR!
To ensure the community can capitalize on this, the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit will be returning this June (20 – 22) in Boston, MA – dedicated to bringing together 80+ industry experts to tackle the biggest problems the field continues to face in discovering translating and clinically developing CD73, CD39, A2A and A2B focused therapeutics.
Join this unmissable 3-day meeting to explore the biology of the receptors and enzymes opening doors to new therapeutic opportunities at the discovery stage, utilize novel technologies and approaches through translation to clinical development to improve patient selection, and discover new ways of finding mono and combo therapy approaches to increase potency and safety.
Top Speakers includes:

Alex Gaither, Vice president from Exscientia AI – evaluating ways to improve preclinical engineering practices for adenosine mono & combo therapeutics candidates
Changyun Hu, CSO from Adept Therapeutics – deep diving into preclinical and clinical Adenosine receptor targeting and more
Joanne Lager, Chief Medical Officer from iTeos Therapeutics – looking beyond T Cell and assessing potential outcomes for the Adenosine field in the event of an approval or major failure

& 15+ more expert speakers!
Download your copy of the newly released agenda to find everything that will help you translate and clinically develop your adenosine therapeutic: https://ter.li/hende5
Interested in speaking? Contact info@hansonwade.com
Interested in sponsoring? Contact sponsor@hansonwade.com

Antimicrobial Resistance Connect Europe
2023-06-21 - 2023-06-22 | LONDON,UK
This event will take place in London on 21-22 June 2023 in London, focusing on the three biggest priorities enabling growth in the AMR field – Innovation, Investment & Policy – AMR Connect enables you to foster connections with key stakeholders in anti-microbial research and build actionable next steps to combat the silent pandemic.

AMR Connect provides your team with the opportunity to create actionable steps within an interdisciplinary environment, creating a unified approach across sectors. The demand to innovate and advance the way we tackle resistance is paramount and commanding the attention of nations globally – book your place now and join us in tackling the silent pandemic.
Benefits of attending

With AMR considered one of the top 10 public health threats globally, uncover how different regions are developing effective policy guidelines and incentive schemes that work for their region – with sessions from ReAct Latin America, Asia-Europe Foundation, WHO and many more.
Apply for the Innovation Showcase, showcasing your state-of-the-art research in drug development, diagnostics or one health in front of our room of investors, pharma and solution providers.
Streamline your route from discovery to market through case studies from Arrepath and Madam Therapeutics on the utilisation of AI/ML to reduce drug development timescales.
Meet your next partner and foster connections across stakeholders through future-focussed roundtables on the biggest challenges impacting the field – including regulation, policy and the future of anti-infectives.

Take advantage of the early bird discount ending on 24 March. Book now to SAVE up to £700.

3rd Annual Next Generation Gene Therapy Vectors Summit
2023-06-27 - 2023-06-29 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
As the biggest industry-led meeting on novel vector development, the 3rd Annual Next Generation Gene Therapy Vectors Summit (June 27-29, 2023 | Boston, MA) will bring together 100+ key opinion leaders to help solve the safety, efficiency, and scalability challenges of the next generation of vectors.
Industry heavyweights such as Novartis, Spark Therapeutics, Capsida Biotherapeutics, and Dyno Therapeutics will deliver data-led seminars, workshops, and panels to aid in the progression of promising vector designs from discovery to clinical trials.
Download the brochure to see the full agenda – https://ter.li/b6qdwn
Uniting industry pioneers such as Dave Chu (Capsida Biotherapeutics), Sean Armour (Spark Therapeutics), Eric Kelsic (Dyno Therapeutics), Jing Liao (Alexion Pharmaceuticals), and others – this summit will be your ultimate roadmap to the future of the industry as it upgrades to the next generation of vectors.
Register to attend with your colleagues and get up to 20% off your tickets – https://ter.li/qlplw9

8th Microbiome Movement Drug Development Summit
2023-06-28 - 2023-06-30 | Omni Boston Hotel at the Seaport, 450 Summer Street, Boston, MA, 02210, United States
The 8th Microbiome Movement Drug Development Summit returns in 2023 as North America’s definitive microbiome drug development event – and it’s back bigger and better than ever!
The microbiome-based therapeutic market is rapidly evolving, and it’s more important than ever to showcase the efficacy of microbial-based approaches beyond C. difficile. Discover how drug developers are advancing their understanding of the role of the microbiome in disease and harnessing functionally relevant microbes for live biotherapeutic approaches.
Join us, as we provide in-depth insights into the interactions between the microbiome and metabolic pathways, host-microbe relationships in novel preclinical models, and the application of microbial-based biomarkers in clinical endpoints and diagnostic settings. Our sessions also cover the mechanistic rationale behind combination therapies, new smart clinical trial data, and GMP compliant manufacturing for stable products.
With more speakers, content, and networking than ever before, this is set to be the best version of the event yet and you cannot afford to miss it!
To know more visit: https://microbiome-summit.com/

2nd Digital Biomarkers & Clinical Measures in Neurology Summit
2023-07-11 - 2023-07-13 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
CNS biopharma is rapidly investing in digital technologies to revolutionize clinical identification and monitoring of complex neurological disorders through more objective, frequent, sensitive, and less invasive measures of movement, speech, and cognition.
Returning to Boston, the 2nd Digital Biomarkers & Clinical Measures in Neurology Summit is the only industry-specific meeting dedicated to developing translatable, scalable, and successful digital technologies and measures specifically to be incorporated into neurological clinical trials.
This is your must-attend meeting tackling the development of digital measures to revolutionize clinical assessments across neurological drug development.
Uniting Digital Health Biopharma with CNS Clinical Drug Developers to:

Address the Standardization & Regulatory Acceptance of Digital Tools & Data Analysis as Endpoints in Complex Neurological Indications
Discover Novel Innovations for Objective, Sensitive, & Non-Invasive Neurological Measures
Ensure Confidence & Scalability with Emerging Digital Technologies

To know more visit: https://ter.li/nx0m2f

2nd Annual Optimizing AAV Safety Summit 2023
2023-07-11 - 2023-07-13 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
With more than 300 trials in preclinical and clinical development actively using AAV as their vector of choice, the priority for any company working in this space is to ensure that each and every one of those therapies is the safest version it can be.
In this context, the 2nd Annual Optimizing AAV Safety Summit is returning in 2023, bringing together genetic therapy leaders across non-clinical development, clinical development, toxicology, biodistribution, and immunology who are all working to optimize the safety of their AAV-based drug products in their day-to-day.
By addressing key topics including how to extract the most relevant data from preclinical studies to better inform how humans will respond to an AAV-based therapy in the clinic, analyzing potential integration risks of AAV serotypes, and investigating regulatory approaches to safety packages for submission, this meeting will inform how to streamline AAV safety processes to de-risk delays and shorten timelines to approval.
Join us in Boston to be part of the solution to bringing safer, effective genetic therapies to patients and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development.
To know more visit: https://ter.li/6gzgy4

Advanced Wound Care Summit US 2023
2023-07-12 - 2023-07-13 | Boston, Massachusetts
The Advanced Wound Care Summit is wound care’s only industry-led forum
It’s a chance for senior executives to address shared challenges around innovative product development, build meaningful partnerships, and sharpen their R&D and commercial strategies.
Whether an established wound care company, an emerging startup, an SME, a regulator, a payer, or key opinion leader, this event serves your strategic and commercial goals.
To take this chance to uncover how leading figures are leveraging novel clinical trial designs, addressing reimbursement challenges surrounding skin substitute products, progressing next generation diagnostic innovations, and much more.
To know more visit: https://hubs.ly/Q01J-t480

3rd Tumor Myeloid-Directed Therapies Summit
2023-07-18 - 2023-07-20 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
The 3rd Annual Tumor Myeloid-Directed Therapies Summit returns with over 75% new speakers to share insights across a range of myeloid targets, including CD40, CD39, LILRB2, CLEC-1 as well as CAR-M therapies. The one-stop shop continues to be your go-to forum to accelerate myeloid therapy progression by determining optimal combination strategy, optimize translational studies, discover novel targets, and guarantee patient safety. Connect with this up-and-coming community to reinvent targeting and harness the untapped potential of the myeloid.
Collaborate and learn from myeloid experts across industry and academia over 3 in-depth days of content, as they address the key bottlenecks limiting the efficacy and safety of these exciting treatments, including in vivo models, biomarkers of response, combination rationale, and myeloid biology to accelerate myeloid directed therapies.
To know more visit: https://ter.li/tm1bzy

ADC Toxicity Summit
2023-07-25 - 2023-07-27 | Hyatt Regency Boston Downtown, One Ave. de Lafayette, Boston, MA, 02111, United States
There is a vast number of ADCs that never make it to the clinic let alone to market, and this is largely due to toxicological challenges providing a narrow therapeutic index. Understanding the causes of toxicity, their translatability into the clinic, as well as mitigation and dosing strategies to limit these toxicities will enable ADC developers to take more assets into the clinic while reducing the costs of failures.
The inaugural ADC Toxicity Summit is coming to Boston, MA this July 25-27 as the first and only meeting dedicated to enabling drug developers to analyze mechanisms of action, discuss shared challenges associated with translating in vivo toxicity data to the clinic, and optimizing dosing to minimize the toxicity of your drug and improve tolerability to bring more ADCs with a wider therapeutic index to market.
Take a look at our 3-day event guide for your in-depth roadmap to the ADC Toxicity Summit.
Uniting all key stakeholders invested in this conversation ranging from toxicologist and pathologists, through to nonclinical, translational, and clinical experts, this is your exclusive opportunity to harness never before gained insights to deliver a safer and more tolerable generation of ADCs to patients.
3 reasons why you can’t miss out on joining include:

Select optimal preclinical models for determining ADC toxicity profiles to enable improved translatability and ultimately improve clinical trial outcomes with Seagen and AbbVie
Hear how companies with commercially approved ADCs mitigated toxicities in the clinic, and optimized their dosage allowing expansion of their therapeutic windows with ImmunoGen and the Dana Farber Cancer Institute
Uncover ideal linker stability and drug-antibody ratios to design an ADC with a lower toxicity profile with Bristol Myers Squibb, Iksuda and Merck & Co

Harnessing case-study led presentations and interactive discussions to enable you to select optimal models for your GLP toxicity studies, mitigate ADC related toxicities in the clinic and optimize linker-design for more controlled payload release, this is your exclusive opportunity to harness new insights to minimize the toxicity of your drug.

2nd Annual Targeted Radiopharmaceuticals Summit
2023-07-25 - 2023-07-27 | Westin Boston Seaport, 425 Summer Street, Boston, MA, 02210, United States
With the exciting news that Novartis has received US FDA approval for Pluvicto for previously-treated patients with PSMA-positive metastatic castration-resistant prostate cancer, the TRP space is continuing to go from strength to strength.
This is why the upcoming 2nd Annual Targeted Radiopharmaceuticals Summit US program is even more comprehensive than ever, bringing you a tracked agenda covering the whole TRP landscape from discovery, translation, to clinical, late stage progress and challenges – a unique opportunity for your entire team to learn and network.
Join us to:

Explore the novel target selection to re-route targeted radiopharmaceuticals from a niche-label therapeutic
Navigate the regulation and reimbursement challenges to improve the accessibility of targeted radiopharmaceuticals
Review theragnostic in the clinic to exploit the two-birds-one-stone potential of TRPs
Discover the potential combination therapies with DDRi’s and IO to unlock synergy with other modalities
Harness the platform technologies for optimized preclinical evaluation of drugs

All presented by top industry players such as Clarity Pharmaceuticals, SOFIE Biosciences, Lantheus, Fusion Pharmaceuticals, Rayze Bio, Telix Pharmaceuticals, OranoMed, Actinium Pharmaceuticals, and many more.
Download the brand-new event guide here to see a full overview 3-day content and speaker faculty: https://ter.li/8hn0z2

Fusion Protein Engineering & Developability Summit
2023-07-25 - 2023-07-27 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
Design & Engineer Functional & Manufacturable Novel Fusion Proteins
Prepare to be captivated by the Fusion Protein Engineering & Developability Summit, the ultimate event tailored to drug developers with groundbreaking fusion protein pipelines. This conference is an absolute game-changer that should be at the top of your priority list!
As the demand for practical and effective engineering techniques to expedite the development of viable drugs into clinical applications skyrockets, this highly anticipated summit offers an unrivalled opportunity. Join forces with esteemed experts from industry giants like Roche, Merck, Bristol Myers Squibb, Abbvie, and an array of other distinguished names. Seize this unique occasion to connect with fellow drug developers, exchange innovative ideas and strategies, and gain invaluable insights into cutting-edge fusion applications.
Prepare for a whirlwind of activity across the action-packed three-day agenda, including:

Cutting-Edge Insights: Gain exclusive access to the latest breakthroughs in fusion protein engineering, encompassing the most recent research and emerging trends in this dynamic field.
Practical Learning: Immerse yourself in hands-on workshops led by industry experts, designed to enhance your skills and knowledge in must-know areas.
Real-World Case Studies: Immerse yourself in over 17+ data-driven case studies presented by renowned drug developers, offering profound insights and best practices.
Engaging Discussions: Engage in lively panel discussions and roundtable sessions, fostering debates and knowledge exchange on hot topics such as novel linker selection and the identification of PK/PD rules.
Networking Opportunities: Forge valuable connections with 60+ protein engineers, therapeutic developers, and influential industry leaders during 7+ hours of dedicated networking, including the renowned speed networking session.

With a stellar lineup of 25+ speakers, 3 immersive hands-on workshops, and 2 days packed with data-driven case studies, this event is set to become the unequivocal highlight of the year and you cannot afford to miss it!
To know more visit: https://ter.li/uuyrdu

4th Gamma Delta T Therapies Summit
2023-07-25 - 2023-07-27 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Established industry leaders and emerging innovators such as Adicet Bio, IN8Bio, Sanofi, Merck, LAVA Therapeutics, Takeda and Leucid Bio are driving the race to demonstrate the potential of Gamma Delta T Therapies as cytotoxic, off-the-shelf solid tumor therapies, spurred by early indications of clinical efficacy.
The 4th Gamma Delta T Therapies Summit returns to Boston this July as the ultimate Industry-focused forum to advance your Gamma Delta T research, spanning dedicated 2 tracks of content to maximize your Clinical & Product Optimization and Research & Translational Development. Join 150+ expert industry peers for 2 full days of sessions and a pre-conference workshop and deep-dive day, building on early clinical successes, highlighting process and engineering innovations and leveraging early clinical insights to cast the spotlight onto Gamma Delta T Therapies in the clinic.
To know more visit: https://ter.li/69o2yc

3rd mRNA-Based Therapeutics Summit
2023-07-26 - 2023-07-28 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
The 3rd mRNA-Based Therapeutics Summit returns to Boston this July, cementing its position as the world’s only end-to-end meeting focused on the next generation of mRNA-based therapeutics and vaccines.
Download the event program here.
This year’s meeting promises 75+ deep-dive case studies from a speaker faculty that is 85% new for this year’s agenda, featuring presentations from the FDA, Pfizer, Moderna, BioNTech, Sanofi and many more.

Expect 100+ world-class speakers from large pharma, innovative biotechs, and key opinion leaders of academia, 5 dedicated tracks and 3 days of immersive content on discovery, translation, clinical development, chemistry, manufacturing and controls (CMC) and logistics to overcome industry hurdles of optimized dosing, targeted delivery, safety and scalability to achieve regulatory success in infectious and rare diseases, cancer and beyond!
Register your team here to join 500+ mRNA experts in July.

2nd ADC Linker & Conjugation 2023
2023-08-22 - 2023-08-24 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
Investments in linker and conjugation technologies have become the single-biggest area of investments within the ADC field, showing how they are being used as key levers for ADC drug developers to pull to create ADCs with a widened therapeutic index.
The inaugural ADC Linker & Conjugation Summit has been specifically designed to drive innovations in linker and conjugation chemistries that result in stable ADCs, with low aggregation and controlled release, which can be replicated at scale.
See the complete event guide here.
Here’s a snapshot of our speaker faculty, including expert industry leaders such as:

Sayumi Yamazoe, Senior Principal Scientist, Bristol Myers Squibb
Romas Kudirka, Director, Chemistry & Bioconjugation, Bolt Biotherapeutics
Donglu Zhang, Senior Fellow, Genentech
Paul Song, Chief Scientific Officer, Genequantum
Patrick Higgs, Principal Scientist, Chemistry, Iksuda
Noah Bindman, Principal Scientist, Seagen
Marc-André Kasper, Director, Chemistry & Early Discovery, Tubulis
Paul Sauter, Director, Chemistry, VERAXA

…and many more!
Find the full list of speakers and session details here.
Be part of the first industry-dedicated meeting for professionals just like you, interested in learning about developments in the field of ADC linkers and conjugations, and overcoming common challenges with stability.

RNA Assay Development & Screening Summit
2023-08-23 - 2023-08-24 | The Bostonian Boston, 26 NORTH STREET, BOSTON, MA, 02109, United States
Bringing together technical experts from biopharma and academia, the brand-new RNA Assay Development & Screening Summit has been curated to support in-house assay development and screening strategies to find new RNA targets, and ultimately determine biological effect in a manner that supports progression from early discovery to drug candidate.
Developed in collaboration with experts in the field, join 60+ key opinion leaders from the likes of Arrakis Therapeutics, Expansion Therapeutics and NextRNA at the first technical RNA meeting of its kind!
Come away with actionable insights after deep diving into the latest technical expertise and explore learnings from data-driven case studies.
Don’t miss this unique opportunity expand and validate your assay and screening strategies and accelerate the path to the clinic! Learn more – https://ter.li/8fsu01

8th CAR-TCR Summit
2023-08-29 - 2023-09-01 | Hynes Convention Center, 900 Boylston St, Boston, MA, 02115, United States
Last year was momentous for the cell therapy field: it was the year that CAR-T therapies became CURATIVE.
This decade of success has resulted in explosive investment into the development of CAR and TCR based approaches to ensure more patients around the world can benefit from these lifesaving therapies.
The 8th CAR-TCR Summit is returning to Boston as the industry’s trusted, definitive, end-to-end forum for the global network of autologous and allogeneic cell therapy drug developers. Ensure your whole team stays ahead of the curve with unmatched industry insights shared across discovery through to commercialization.
Across 3 conference days with 8 content tracks, and an additional 6 deep-dive workshops, bootcamp, focus day, diversity session, C-level think tank and more, 200+ CAR and TCR experts will lead you and over 1,000 peers in discussions that will accelerate your pipeline, bringing better drugs to patients faster.
To know more visit: https://ter.li/ztgick

2nd Oligonucleotides CMC & Analytical Development Summit 2023
2023-08-29 - 2023-08-31 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Rapid development and rising demand of oligonucleotide drugs is fuelling revolutionary steps in biopharma investment and technology advancement for pipeline progression. The prospect of defining impurities and suitable CQAs for long-term scalable manufacturing looks to propel oligonucleotide development to patients at a much faster rate.
The 2nd Oligonucleotides CMC & Analytical Development Summit returns this August to Boston. 70+ industry leaders will unite at this unique forum dedicated to CMC and Analytical Experts.
Across 3 days, senior leaders will leverage knowledge and share thought leadership focused on improving analytical characterization, effectively preparing CMC data for IND filing and scaling up with long-term manufacturing in mind.
Built with experts from AstraZeneca, Alexion Pharmaceuticals, Biogen , revolutionize your drug development protocols by keeping your finger on the pulse at this hotly anticipated summit.

Explore analytical control strategies for therapeutic oligonucleotides to ensure safety and quality with regulatory compliance
Overcome the challenges of capacity when out-sourcing to propel and expedite oligonucleotide development
Get interactive in roundtable discussions, picking the brains of your peers and expert speakers on how biopharma is currently navigating the regulatory landscape
Facilitate cost-efficient large-scale production of oligonucleotides now we are moving into larger patient populations and non-rare disease indications
Turbocharge novel and complex oligonucleotide development in an in-depth workshop outlining CMC, Analytical Characterization and Impurity Control of conjugates

Download your Full Event Guide Here for more details on what you can expect at the 2nd Oligonucleotides CMC & Analytical Development Summit. Including the expert speaker faculty, a full in-depth agenda and the incredible networking and collaboration opportunities on offer this year.

3rd Inner Ear Disorders Therapeutics Summit
2023-08-29 - 2023-08-31 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The development of next-generation drug-based approaches to treat inner ear disorders is gaining momentum, with multiple INDs approved in the last six months and big pharma making plays to acquire innovative biotechs working on hearing loss.
However, in a space that has also had to battle with multiple clinical failures, there’s a genuine need for the industry to unite and overcome the specific obstacles that are currently acting as a barrier to late-stage clinical trials and through to approval.
That’s why the 3rd Inner Ear Disorders Therapeutics Summit is back this summer, bringing together the community to collectively accelerate development of drug-based approaches, sharing case studies and data-driven insights into optimizing preclinical programs and designing translational studies to ultimately validate clinically relevant targets.
This meeting will leverage the latest biotech and academic innovation alongside big pharma experience to address the technical and strategic challenges in delivering a safe and effective therapy to the inner ear.
What to expect from the 2023 meeting:

Explore how to improve clinical trial design to increase the number of clinical trials achieving regulatory approval
Delve into the numerous delivery methods being employed in industry and explore how to optimize delivery to the inner ear
Evaluate the current opportunities and limitations of using animal models to accurately predict preclinical efficacy and translational success
Leverage valuable insights from VC investors to understand the key considerations made when investing in or forging partnerships with biotechs focussing on inner ear disorder therapeutics
Navigate the complex landscape of improving the diagnostics of inner ear disorders by developing a robust diagnostic toolbox and strategizing how to supplement patient-reported outcome measures

View the full agenda here: https://ter.li/a2ivra

5th Exosomes Based Therapeutic Development Summit
2023-09-05 - 2023-09-07 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
The 5th Exosome Based Therapeutic Development Summit returns with a refreshed program, with data-driven insights from those pioneering the field who are dedicated to the clinical translation and commercialization of exosome-based therapeutics across a broad range of disease indications.
This year features a brand-new focus day on analytical development, diving into characterization assays, purification, and potency assays to enable robust translation into the clinic.
This is the most comprehensive, end-to-end meeting for industry personnel who are looking to fine-tune molecular components of exosomes, achieve GMP manufacturing of EVs for clinical applications, and successfully deliver payloads to the target tissue by evaluating route of administration to accelerate candidates towards commercialization.
The 2023 conference covers:

Emerging standardized analytical strategies for optimized characterization, purification, and isolation to improve batch consistency and reproducibility towards successful scale-up
Key pre-clinical and clinical updates across a range of therapeutic areas
The latest advancements of targeted delivery and therapeutic payloads
The challenges of large-scale manufacturing
Navigating the complex regulatory landscape across the drug development timeline

View the full agenda here: https://ter.li/q4fnpd

4th Annual Gene Therapy Immunogenicity Summit 2023
2023-09-05 - 2023-09-07 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The 4th Annual Gene Therapy Immunogenicity Summit is your opportunity to connect with likeminded peers from gene therapy drug developers, along with leading academics, regulators, and key service providers, all making strides with improving risk assessments, monitoring, and mitigating against AAV gene therapy immunogenicity.
Registering for 2023 will grant you access to keynote plenaries from leading gene therapy figures, deep-dive discussions into pressing preclinical and clinical developments, and highly appraised networking opportunities with 150+ of your peers, all to leave you with the actionable tools, insights, and connections you need to enhance your immunogenicity-focused work.
To know more visit: https://ter.li/vk8xwq

13th World Clinical Biomarkers & CDx Boston 2023
2023-09-05 - 2023-09-08 | Omni Boston Hotel at the Seaport, 450 Summer Street, Boston, MA, 02210, United States
The hotly anticipated 13th World Clinical Biomarkers & CDx Summit returns as the only industry-led meeting uniting 600+ senior decision makers in the biomarker and CDx field to accelerate clinically validated and affordable co-development of drug-CDx by overcoming commercialization, reimbursement and regulatory challenges in oncology and beyond to bring personalized medicine to patients faster.
Whether you are working in Oncology, NASH, or Neuroscience, join 600+ Directors, Heads and VPs of Clinical Biomarkers, Translational Medicine, Precision Medicine & Companion Diagnostics together with drug and diagnostic developers, regulatory experts, payors and notified bodies for an exclusive opportunity of knowledge sharing and networking to propel your pipelines and make a marked difference for patient outcomes.
To know more visit: https://ter.li/849j6q

7th Complement-Based Drug Development Summit
2023-09-11 - 2023-09-13 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
With the recent FDA approval of SYFOVRE and more decisions and approvals expected in 2023, the Complement-Based Drug Development Summit is returning for its 7th year in a timely fashion. Be the first to view this year’s Event Guide below!
7th Complement-Based Drug Development Summit
September 11-13, 2023
View Agenda
Reuniting experts across Nephrology, Neurology, Ophthalmology, and Haematology, join the leading companies showcasing the latest preclinical and clinical progress for complement-based therapeutics.

With 30+ expert speakers from: AGTC, Alexion, Alnylam, Amgen, Annexon, Apellis – and that’s just the A’s!
Covering more complement targets than ever before including C5aR2, Factor Bb and Combination Therapy, alongside an increased coverage of diseases
Full of content for your whole team covering the most pressing challenges – from evaluating the value proposition of different fragments to target to designing clinical trials with high-risk patient populations

​​​​View the full list of sessions and expert speakers here.
​​​​​​This world-class speaker faculty will evaluate the entirety of the complement landscape, from scientific understanding to strategic, commercial intelligence. This means that no matter your role in the field, you’ll leave with tangible insights to further develop your complement pipeline.

LNP Characterization & Analytical Development Summit
2023-09-12 - 2023-09-14 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Fingerprinting Your LNP Drug Product Quality, Safety, Efficacy & Regulatory Compliance
With the recent breakthroughs from Verve Therapeutics, Vertex-Arbor Bio, and Mana.bio propelling the field of LNP technology forward at lightning speed beyond mRNA vaccines, the LNP Characterization & Analytical Development Summit is your must-attend meeting to deep dive into the latest technologies and approaches throughout product lifecycle and strengthen your lipid nanoparticle characterization, bioanalytical and assay development competencies.
With unmissable case studies from the likes of Pfizer, Moderna, AstraZeneca, Ultranegyx, Merck and SINTEF, this is the definitive forum to benchmark and learn with the LNP community who unite for the first time.
These industry titans have collaborated to form a comprehensive, 3-day program covering key topics including:

Analyze LNP structure and morphology to relay into functional data and analytical practices with Ultragenyx and Pfizer
Optimize the characterization of payloads to foresee the outcome of the LNP complex with Hopewell Therapeutics, Beam Therapeutics and Moderna
Develop assays which align with mechanisms of action and portray total functionality of the LNP with NIST, Editas Medicine and AstraZeneca

Don’t miss this opportunity to supercharge your analytics, and together with 60+ characterization and analytical scientists, get inspiration to derive best practice, and support next generation of therapeutics to patients with safety and efficacy.
To know more visit: https://ter.li/z7dmih

3rd Rare & Genetic Kidney Disease Drug Development Summit
2023-09-12 - 2023-09-14 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Your one-stop shop to capturing industry’s most exciting developments to tackle rare & genetic kidney diseases. From evaluating real-world outcomes to uncovering underlying pathophysiology to interrogating translational models, the 3rd Rare & Genetic Kidney Disease Drug Development Summit is uniquely positioned to give industry the opportunity to unite towards a shared goal and share strategic insights to move from bench to bedside and bring efficacious therapies to patients faster.
To know more visit: https://ter.li/jy2ot0

Wearable Injectors and Connected Devices USA
2023-09-13 - 2023-09-14 | Sheraton Boston Hotel, 39 Dalton Street, Boston, MA, 02199, United States
Wearable Injectors and Connected Devices USA
Conference: September, 13 – 14 2023
Boston, USA
Website: http://www.wearableinjectors-usa.com/PharmaJournalist-EL
Advancing digital health and on-body drug delivery devices for enhanced patient experience
Following the success of the Wearable Injectors and Connected Devices Europe conference, SAE Media Group will be bringing the conference to Boston to cater to Big Pharma, Biotech and Device Developers in the USA.
As the need for at home self-administration and routes for delivery of time-dependent and high-volume drug delivery grows, on-body injectors and connected devices hold great opportunity. The conference will delve into on-body device design and development, latest advances in connectivity and digital integration of wearable devices, and opportunities for enhancement of user-interface through human factors case studies. The conference will also address challenges in regulations surrounding wearable injectors and connected devices with case studies and an FDA keynote on cybersecurity.
As part of SAE Media Group’s leading Injectable series of conferences, we bring together high-level experts from big pharma and device developers to network and share knowledge to advance R&D. The two-day conference will not only bring you high-quality key insights needed to enhance your wearable devices and connected product portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in September 2023!
Key Reasons to Attend:

Discover the latest advances in wearable injector design and development as well as emerging technologies for improved drug delivery
Understand and gain insight into the regulations surrounding electronic devices and wearable injectors such as labelling requirements and clinical study expectations
Delve into the digital integration of medical devices for improved user experience and strategies to ensure connected ecosystems are safe with an FDA Cybersecurity update
Benchmark against connected injector case studies and gain insight into key considerations during development such as battery selection
Engage in the latest strategies for implementing user centricity into device design to meet patient needs and increase adherence

WHO SHOULD ATTEND?
Device Developers
Combination Product Developers
Smart Packaging Developers and Designers
Smart Device Developers
Drug- Delivery Developers
Connected/Digital Health Developers
